Medical Economics January 17, 2025
Staff

Key Takeaways

  • Medicare will negotiate prices for Ozempic, Wegovy, and Rybelsus, targeting cost reductions for expensive drugs.
  • The Inflation Reduction Act empowers these negotiations, aiming to improve drug affordability for seniors.
  • Pharmaceutical companies must decide by February 28 to participate in negotiations, with new prices effective in 2027.
  • The initiative seeks to save billions and enhance Medicare’s sustainability for future generations.

New prices would take effect in 2027.

Ozempic (semaglutide), the Type 2 diabetes drug that has become popular for weight loss, and Wegovy, the form of the drug approved for patients to shed pounds, are on the list for Medicare drug price negotiations in 2025.

Rybelsus, the oral form of semaglutide, also is on the list announced...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Medicare reimbursement rates explained: Why they keep declining, and what the future holds
Medicare Drug Coverage Is Often Inadequate—Here’s Why
Medicare Drug Price Negotiations: Who really benefits?
CMS Announces Selected Drugs for 2027 Maximum Fair Price Negotiations; New Administration Issues Executive Order Affecting the IRA - Then Clarifies
GOP calls for $1.5T in cuts, much of which could come from healthcare

Share This Article